Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS0101 With or Without Pembrolizumab in Neoadjuvant Treatment of HPV-Associated Oropharyngeal Cancer
NCT05232851Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PDS0101 in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Proportion of Pathologic and Human Papillomavirus Cell-free Tumor Deoxyribonucleic Acid (ctHPVDNA) Response at 2 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
PDS0101
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT05232851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232851.